Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 42Terminated 19Recruiting 8Unknown 7Active not recruiting 5Not yet recruiting 3Suspended 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Neoplasms 12Leukemia, Myeloid, Acute 12Neoplasm Metastasis 9Melanoma 7Breast Neoplasms 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Ovarian Neoplasms 6Colorectal Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Myelodysplastic Syndromes 5Lung Neoplasms 5Glioma 5Hematologic Neoplasms 4Glioblastoma 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Solid Tumors 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Sarcoma 2Osteosarcoma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, B-Cell 2

Interventions

Azacitidine 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Suspended × Lymphoma, T-Cell, Peripheral × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04828174 2023-11-29

Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1 Suspended
9 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Peripheral, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡